AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02432209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate physical activity
Description: All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
Study NCT02432209 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moderate physical activity
Description: All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
Study NCT02106741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation acupressure
Description: The relaxation acupressure protocol will use a set of nine fixed acupoints: forehead, twixt the eyebrows (unilateral); posterior neck, behind the ears (bilateral); palmer side of hand at wrist (bilateral); inside of lower leg (bilateral); top of foot (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes.
Study NCT02106741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimulating acupressure
Description: The stimulating acupressure protocol will use a set of ten fixed acupoints: top of the head (unilateral); below the navel (unilateral); back of the hand (bilateral); outside of lower leg (bilateral); inside of lower leg (bilateral); inside of ankle (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes.
Study NCT01486823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLDL1278A
Description: Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
Study NCT01486823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLDL1278A
Description: Single subcutaneous dose of 360 mg MLDL1278A.
Study NCT00893529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lemonade with sugar
Description: 250 milliliters of lemonade with sugar daily for 18 months
Study NCT00893529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lemonade low in sugar
Description: 250 milliliters of lemonade low in sugar daily for 18 months
Study NCT03092648 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchial basal cell
Description: autologous bronchial basal cell transplantation
Study NCT02273128 — intervention group
Intervention type: GENETIC
Intervention: CTR Gene
Description: 2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
Study NCT04285905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Access to Fast Track TB clinic
Description: Male partner can attend clinic with dedicated services for men
Study NCT04285905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information leaflet for male partner
Description: Female participants will be provided with a letter asking their male partner to attend the clinic for tuberculosis screening
Study NCT04285905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home sputum collection
Description: Female participants will be provided with sputum cups to take home and collect a sample of sputum from their male partner
Study NCT04285905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home HIV testing
Description: Female participants will be provided with an oral HIV self-test kit to be given to their male partner with instructions for use
Study NCT04285905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentive
Description: Female participants will be provided with a voucher for MKW5000 which can be redeemed when the male partner attends the clinic for TB testing
Study NCT04388176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21 as first treatment
Study NCT04388176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21 as second treatment
Study NCT04388176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as second treatment
Study NCT04388176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as first treatment
Study NCT02934555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubiquinol
Description: 300 mg Ubiquinol (3 mL liquid Ubiquinol).
Study NCT02934555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ensure
Description: 50 mL Ensure
Study NCT02934555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: 50 mL Ensure
Study NCT01199887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW001
Description: IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
Study NCT05857410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmetomidine
Description: Dexmetomidine (H20183219) 0.4μg / (kg·min)；
Study NCT05857410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmetomidine
Description: Dexmetomidine (H20183219) 0.4μg / (kg·min)；
Study NCT05857410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower limb heating blanket
Description: Beijing Maikang Medical Device Co., Ltd., Model: Warm-1-1.
Study NCT05857410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lower limb heating blanket
Description: Beijing Maikang Medical Device Co., Ltd., Model: Warm-1-1.
Study NCT04291118 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Private system endoscopic sinus surgery
Description: Patients that will undergo endoscopic sinus surgery though the private system. Beforehand they could of used medical management including, budesonide for their symptoms.
Study NCT04291118 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Public system endoscopic sinus surgery
Description: Patients that undergo endoscopic sinus surgery though the public system after waiting for at least 1 year. Beforehand they could of used medical management, including budesonide for their symptoms.
Study NCT04291118 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide
Description: Patients will receive medical management for their symptoms that will consist of topical nasal steroid, budesonide and any other required medication for their disease.
Study NCT01423929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Fitting of Oxymask TM and treatment with 10 L O2/min
Study NCT01423929 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Room air
Description: Fitting of Oxymask TM
Study NCT02555917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior cruciate ligament reconstruction
Description: Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
Study NCT02555917 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior cruciate ligament reconstruction
Description: Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
Study NCT00200577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL + IL2
Description: Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
Study NCT04337021 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver SOS
Description: SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
Study NCT00758381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg po bid, continuously
Description: NEXAVAR\*112CPR RIV 200MG~Titolare AIC:~BAYER SpA~Numero di AIC dell'IMP:~037154010
Study NCT00758381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabina, Cisplatino
Description: Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
Study NCT00048633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study NCT04900649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest resistance exercise
Description: lung function.
Study NCT04900649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest expansion exercises
Description: thoracic excursion
Study NCT01403571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salba (Salvia hispanica L.)
Description: 30g/1000kcal/day over 24 wks
Study NCT01403571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oat-based Control
Description: Placebo: 36g/1000kcal/day over 24 weeks
Study NCT02344511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Drug
Study NCT02344511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin, nafcillin, oxacillin or vancomycin
Description: Standard of Care
Study NCT04636411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Magnesium Supplementation
Description: 250 mg of elemental magnesium daily for three months
Study NCT04636411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care for diabetic patients
Description: Health education, oral antihyperglycemic medications according to American Diabetes Association (ADA) guidelines
Study NCT04636411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care for diabetic patients
Description: Health education, oral antihyperglycemic medications according to American Diabetes Association (ADA) guidelines
Study NCT01319942 — intervention group
Intervention type: OTHER
Intervention: Radiotherapy combined with sorafenib
Description: Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
Study NCT01388712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10\^8CFU).
Study NCT01388712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
Study NCT03914274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technical sock
Description: Socks were of two types: technical socks, designed for high performance sports use (Lurbel brand, models Tierra and Set), and non-technical socks for everyday use. The socks had different composition: Tierra (50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra); Set (75% cotton, 17% polyamide, 8% lycra) and cotton (98% cotton, 2% elastane).
Study NCT02729480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halo Craniofacial Nerve Stimulator System
Description: The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
Study NCT02729480 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Halo Craniofacial Nerve Stimulator System
Description: The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
Study NCT02149264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel (FE 999303)
Study NCT04329845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open splenectomy
Description: open splenectomy for treatment of splenic injury
Study NCT04329845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic splenectomy for splenic injury in trauma
Description: laparoscopy as a technique for removal of the spleen in injury
Study NCT01610869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
Study NCT01610869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIBF 1120
Description: Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
Study NCT01184170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: overfeeding
Description: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
Study NCT03293017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam 10 MG
Description: If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
Study NCT03293017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diazepam 10 MG
Description: If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
Study NCT03293017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 30mg
Description: Baclofen 30 mg/day given over three gifts daily
Study NCT03293017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 60mg
Description: Baclofen 60 mg/day given over three gifts daily
Study NCT04086121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for SC injection
Study NCT03967041 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: radiological defined sarcopenia
Description: Evaluation for sarcopaenia was performed via calculating psoas cross-sectional area at level of L3 and normalising for height
Study NCT02317484 — intervention group
Intervention type: DRUG
Intervention: Ipragliflozin (SGLT2 inhibitor)
Study NCT03202446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Glycated Chitosan
Study NCT03202446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photothermal Laser
Study NCT03202446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03202446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT03202446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study NCT03507985 — intervention group
Intervention type: OTHER
Intervention: Two tests evaluating memory and attention
Description: The patient will perform two tests assessing memory and attention:~Regarding attention, the test used will be the Stroop Color Word Test, developed to measure visual selective attention, cognitive flexibility and inhibition.~For memory, the test used will be Rey's 15 words test. It provides an indicative standard for the evaluation of episodic verbal memory and learning abilities. This test was compared to the 16-item (18) free recall / booster test in normal aging and Alzheimer's dementia, and although it was more difficult, it . Since it allowed for the classification of participants from both groups without overlap
Study NCT02360488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Therapy
Description: 18 days of supervised sessions via videoconference and 18 days of unsupervised sessions.
Study NCT02360488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Clinic Therapy
Description: 18 days of therapist supervised sessions and 18 days of unsupervised in home sessions.
Study NCT00005067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin lutetium
Description: Given IV
Study NCT00005067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo photodynamic therapy
Study NCT02413632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: creation of a STIs score risk
Description: 4 questionnaires 3 screening test ( syphilis, chlamydia, gonorrhea)
Study NCT02413632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: validation of a STIs score risk
Description: DRIVER questionnaire (DRIVER STI score risk) 3 screening test ( syphilis, chlamydia, gonorrhea)
Study NCT03705286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVAC-PU-ETT
Description: Placement of a EVAC-PU-ETT in the setting of emergent intubation.
Study NCT02890355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02890355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT02890355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV bolus
Study NCT02890355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02890355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02890355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03705286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC-ETT
Description: Placement of a PVC-ETT in the setting of emergent intubation.
Study NCT04208672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UMindSleep
Description: CPAP titration will be provided for Obstructive Sleep Apneas Syndrome.
Study NCT02841358 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Study NCT02841358 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biopsy
Study NCT00000256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% N2O
Study NCT00000256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% N2O
Study NCT00000256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60% N2O
Study NCT00000256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80% N2O
Study NCT03161067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiCNS
Description: Surgical implantation
Study NCT02833064 — intervention group
Intervention type: RADIATION
Intervention: Non-contrast magnetic resonance imaging
Study NCT02833064 — intervention group
Intervention type: OTHER
Intervention: Biological sampling
Description: Blood, urine, stool and breath sampling and analysis
Study NCT02426034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ApatinibTablets
Description: Apatinib Tablets, recommended dose of 850mg
Study NCT00292253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebif® via Rebiject™Mini
Description: Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.
Study NCT00292253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rebif® via manual injections
Description: Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.